Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments
January 21, 2025 08:00 ET
|
Pacira BioSciences
-- Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to support company’s 5x30 path to becoming an innovative...
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
January 10, 2025 08:00 ET
|
Pacira BioSciences
PARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the...
Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
January 07, 2025 08:00 ET
|
Pacira BioSciences
PARSIPPANY, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of...
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025 16:01 ET
|
Pacira BioSciences
PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 AM PT...
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 06, 2024 08:00 ET
|
Pacira BioSciences
PARSIPPANY, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the...
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
December 03, 2024 07:30 ET
|
Pacira BioSciences
-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences,...
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
November 14, 2024 10:05 ET
|
Pacira BioSciences
PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of...
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
November 12, 2024 08:00 ET
|
Pacira BioSciences
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare...
Pacira BioSciences Reports Third Quarter 2024 Financial Results
November 06, 2024 16:00 ET
|
Pacira BioSciences
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative,...
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
November 04, 2024 08:00 ET
|
Pacira BioSciences
-- Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act -- -- Beginning January 1, 2025, providers can receive additional Medicare payment when they use...